Here's why Argenx could keep winning.
ARGX argenx SE American Depositary Shares
XNAS
962.36
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ARGX
$962.36
—
Key stats
$962.36
- 52-Week Range
- $661.85 – $1072.75
- YTD
- +14.57%
- IV Rank (30D)
- 56.15
- Straddle Price
- $100.15
- P/C Vol Ratio
- 1.17
- Market Cap
- $58.3B
- Open
- $945.59
- Day Range
- $935.57 – $965.39
- Volume
- 298,949
- Prev Close
- $927.21
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.62 |
| Cost of Equity (CAPM) | 7.99% (VRP-adj) |
| WACC | 8.09% |
| Volatility Risk Premium | +6.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $930.67 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $869.86 |
| Bollinger Width / SMA20 | 16.8% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $58B |
Peers used for multiples: AMGN, BIIB, GILD, LLY, MRNA, NTRA, REGN, VRTX
60-Day Conviction
20%
20-Day Fair Value
≈ by Dec 8, 2026
$964.28
α +0.1%
rank 45%
conviction
5%
40-Day Fair Value
≈ by Jan 6, 2027
$973.95
α +1.1%
rank 45%
conviction
39%
60-Day Fair Value
≈ by Feb 4, 2027
$956.98
α -0.7%
rank 45%
conviction
20%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.6× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 24.5× · 6 peers |
| Peer P/B | n/a | 0% | median 15.1× · 8 peers |
| Peer P/S | n/a | 0% | median 8.7× · 8 peers |
| Market Anchor (SMA50) | $930.67 | 57% | stability 66% (BB-width) |
| Options Expected (B-L 30d) | $930.01 | 43% | 72 strikes · skew +0.20 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $58.3B
- Employees
- 1,863
- List Date
- 2017-05-18
- CIK
- 0001697862
- Homepage
- https://www.argenx.com
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disor…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -1.35% | -23.30% | 2.26% | -0.13% | 5.64% | 0.06% | -2.80% |
| Feb | 4.18% | 2.51% | -3.61% | -1.44% | -5.00% | -8.23% | -1.93% |
| Mar | -19.13% | 7.04% | 0.98% | 0.06% | -4.94% | -3.50% | -3.25% |
| Apr | 1.54% | -11.70% | 7.70% | -5.49% | 13.76% | 5.19% | 1.83% |
| May | -1.78% | 5.44% | -0.90% | -3.21% | -10.41% | 6.70% | -0.69% |
| Jun | 9.13% | 23.06% | -1.25% | 13.79% | -5.71% | 10.97% | 8.33% |
| Jul | -0.02% | -3.43% | 32.21% | 18.80% | 23.57% | -6.36% | 10.79% |
| Aug | 7.21% | 6.45% | -0.31% | 0.22% | 5.70% | 24.18% | 7.24% |
| Sep | -10.63% | -6.42% | -4.50% | 5.42% | 4.41% | -6.77% | -3.08% |
| Oct | -0.30% | 10.54% | -3.64% | 7.13% | 6.67% | -4.61% | 2.63% |
| Nov | -9.67% | 4.85% | -8.93% | 3.52% | 10.37% | 10.14%* | 1.71% |
| Dec | 23.47% | -5.11% | -16.18% | -0.40% | -6.03% | -- | -0.85% |
| Total | -3.64% | 2.02% | -2.87% | 42.13% | 38.32% | 25.70% | 16.94% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $877.40
SMA 50: $929.47
SMA 200: $857.80
Current: $963.04
EMA 12: $906.24
EMA 26: $900.68
MACD: 5.5547 | Signal: 12.0350
BEARISH
ADX (14): 18.34
RANGE
+DI: 29.71
−DI: 18.61
Momentum Oscillators
RSI (14): 61.64
NEUTRAL
Stoch %K: 86.19
Stoch %D: 85.44
Williams %R: -2.10
Volume & Volatility
BB Upper: $956.03
BB Lower: $798.76
OVERBOUGHT
OBV: 3,426,246
Vol SMA 20: 418,991
Vol ROC: 10.50%
ATR: $31.11
True Range: $38.18
HV 20: 39.8%
HV 30: 51.9%
HV 60: 51.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: ARGX EXECUTIVE SUMMARY: BULLISH (Confidence Level: 7/10)
Key drivers:
- Strong technical momentum, with MACD in bullish territory
- Recent news headlines focus on positive developments and acquisitions
- Low volatility and beta indicate reduced risk
Primary risks:
- Earnings misses or regulatory setbacks could impact sentiment
- Market downturns may lead to increased volatility
Investment thesis: ARGX's recent acquisition of Forte Biosciences, Inc. is expected to drive growth and strengthen its position in the autoimmune myositis market. With a low-volatility profile and bullish technical momentum, this stock has potential for steady appreciation.
Recent news sentiment impact: The recent acquisition news headlines have had a positive impact on sentiment, contributing to the overall bullish tone.
TECHNICAL ANALYSIS:
Trend direction:
- Short-term: Bullish (trending upward)
- Medium-term: Bullish (trending upward)
- Long-term: Bullish (trending upward)
Support/resistance levels:
- SMA 20: $1007.76
- SMA 50: $930.78
- Upper Bollinger Band: $1118.73
Momentum signals:
- MACD: Bullish (above signal line)
- RSI: Neutral (50.21)
- Stochastic %K/D: Bullish (11.42/31.40)
Volume analysis:
- Volume SMA 20: 276957.60
- On-Balance Volume (OBV): 7092427.54
- Volume Rate of Change: -37.46% (indicating reduced trading activity)
NEWS & SENTIMENT ANALYSIS:
Recent headlines summary: ARGX has completed its acquisition of Forte Biosciences, Inc., and the company is poised for growth in the autoimmune myositis market.
Sentiment assessment: Positive (75%), with only one negative headline about Sanofi's trial setback.
Catalyst identification: The recent acquisition and upcoming investor conferences are expected to drive growth and strengthen sentiment.
Market narrative: The positive news flow has aligned with the technical signals, indicating a strong uptrend.
RISK & VOLATILITY ASSESSMENT:
Beta interpretation: 0.34 (low volatility), indicating reduced risk relative to the market.
Volatility regime: Low (0.35), suggesting reduced price movement and increased stability.
Options market signals: IV Rank: 3.8% (Low - shows if volatility is historically high/low) Current IV: 43.5% Expected Move: $85.70 (36 DTE), 7-DTE: $35.85
Downside protection: Support levels at SMA 20 and Bollinger Band Lower.
MARKET CONTEXT & POSITIONING:
Sector performance: ARGX is outperforming its sector, with a strong uptrend in place.
Institutional activity: Volume patterns suggest institutional interest and buying pressure.
Correlation analysis: ARGX has a low correlation coefficient (0.13) with the market, indicating reduced risk and potential for independent price movement.
Relative valuation: ARGX is trading within a defined range, with room for further appreciation.
KEY LEVELS & ACTION ITEMS:
Critical price levels:
- SMA 20: $1007.76
- Upper Bollinger Band: $1118.73
Breakout/breakdown levels:
- SMA 50: $930.78 (breakout potential)
- Lower Bollinger Band: $896.79 (breakdown risk)
Time-sensitive catalysts:
- Earnings dates: No earnings data available
- FDA approvals: None announced recently
Risk management: Stop-loss levels and position sizing considerations will depend on individual investor goals and risk tolerance.
CONCLUSION: ARGX presents a compelling investment opportunity, with strong technical momentum, positive news flow, and reduced volatility. While there are some risks to consider, the overall bullish tone suggests potential for steady appreciation.
Generated
News
All ARGX news →
Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.
VYVGART revenue surged 54% year-over-year amid strategic Forte Biosciences acquisition.
Showing 1–10 of 16
Page 1 of 2
ARGX Options Activity & IV Rank
ARGX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 39.9%
7-DTE IV: 39.9%
Expected Move: $100.15
7-DTE Move: $54.05
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,743
Put Volume: 2,038
P/C Volume: 1.169
NEUTRAL
Call OI: 5,871
Put OI: 5,915
P/C OI: 1.007
Total OI: 11,786
ATM Options Pricing
ATM Call: $53.60
ATM Put: $46.55
Call %: 5.6%
Put %: 4.8%
Chain Summary
Chain Volume: 3,781
Chain OI: 11,786
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 51st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
51%
vs own history
GEX tilt
+0.20
OI-weighted, today
Vanna tilt
+0.42
δ-sensitivity to IV
Charm tilt
-0.43
δ-decay vs time
Vanna tilt +0.42: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.43: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 78 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)47.4MediumNov 9
IV Rank (30 DTE)56.1MediumNov 9
Straddle Price (30 DTE)$100.15Nov 9
Beta Analysis
Risk Metrics
Beta: 0.5325
Alpha: 12.48%
Correlation: 0.1933
R-Squared: 3.7%
Stock Volatility: 37.9%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ARGX
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $197.1M | #195 of 6285 | -3.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $87.6M | #381 of 3716 | +30.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $37.1M | #410 of 1945 | new | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $1.8M | #735 of 997 | +61.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $768K | #1856 of 4729 | -11.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ARGX Institutional Ownership (13F)
Filings for 2026-06-30 · 245 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
14 filers$297.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $66.15M | 22.23% | 2026-06-30 |
| 2 | D. E. Shaw & Co., Inc. Custodian | $54.09M | 18.18% | 2026-06-30 |
| 3 | Barclays PLC Custodian | $47.08M | 15.82% | 2026-09-30 |
| 4 | Citadel Advisors LLC Custodian | $34.05M | 11.44% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $32.84M | 11.04% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $30.59M | 10.28% | 2026-09-30 |
| 7 | LMR Partners LLP | $18.93M | 6.36% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $6.14M | 2.06% | 2026-09-30 |
| 9 | Point72 Asset Management, L.P. | $3.34M | 1.12% | 2026-06-30 |
| 10 | PEAK6 LLC | $2.78M | 0.94% | 2026-06-30 |
| 11 | SIH Partners, LLLP | $927.77K | 0.31% | 2026-06-30 |
| 12 | Walleye Capital LLC | $371.11K | 0.12% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $185.55K | 0.06% | 2026-06-30 |
| 14 | HUB Investment Partners, LLC | $95.89K | 0.03% | 2026-09-30 |
10 filers$148.23M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $78.86M | 53.20% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $22.45M | 15.15% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $20.23M | 13.65% | 2026-09-30 |
| 4 | Jane Street Group, LLC Custodian | $11.13M | 7.51% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $4.70M | 3.17% | 2026-09-30 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $4.45M | 3.00% | 2026-06-30 |
| 7 | LMR Partners LLP | $3.06M | 2.07% | 2026-06-30 |
| 8 | Point72 Asset Management, L.P. | $2.04M | 1.38% | 2026-06-30 |
| 9 | Walleye Capital LLC | $742.22K | 0.50% | 2026-06-30 |
| 10 | Two Sigma Investments, LP Custodian | $556.66K | 0.38% | 2026-06-30 |
ETF Holders
106 ETFs hold ARGX
25 shown · $3.73B total exposure · 0.36% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.13% | $888.8M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.19% | $586.1M | — | 2026-09-30 |
| 3 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.23% | $433.3M | $187.1B | 2026-11-06 |
| 4 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 3.56% | $389.2M | $11.1B | 2026-11-06 |
| 5 | EFA iShares MSCI EAFE ETF | iShares (BlackRock) | 0.27% | $204.0M | $75.5B | 2026-11-06 |
| 6 | VGK Vanguard FTSE Europe ETF | Vanguard | 0.39% | $144.8M | — | 2026-09-30 |
| 7 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.15% | $143.2M | — | 2026-09-30 |
| 8 | CGGO Capital Group Global Growth Equity ETF | Capitalgroup | 1.00% | $114.4M | $11.5B | 2026-11-05 |
| 9 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.74% | $111.0M | $3.0B | 2026-11-06 |
| 10 | EFG iShares MSCI EAFE Growth ETF | iShares (BlackRock) | 0.56% | $82.2M | $14.8B | 2026-11-06 |
| 11 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.14% | $79.3M | $56.4B | 2026-11-06 |
| 12 | EZU iShares MSCI Eurozone ETF | iShares (BlackRock) | 0.78% | $71.8M | $9.1B | 2026-11-06 |
| 13 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.17% | $69.4M | $41.0B | 2026-11-05 |
| 14 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.20% | $68.5M | $33.4B | 2026-11-06 |
| 15 | VT Vanguard Total World Stock ETF | Vanguard | 0.05% | $52.1M | — | 2026-09-30 |
| 16 | FEZ State Street® SPDR® EURO STOXX 50® ETF | SPDR (State Street) | 1.14% | $47.8M | $4.2B | 2026-11-05 |
| 17 | EWK iShares MSCI Belgium ETF | iShares (BlackRock) | 15.60% | $39.8M | $254.9M | 2026-11-06 |
| 18 | IEUR iShares Core MSCI Europe ETF | iShares (BlackRock) | 0.37% | $35.6M | $9.6B | 2026-11-06 |
| 19 | IXJ iShares Global Healthcare ETF | iShares (BlackRock) | 0.64% | $29.8M | $4.6B | 2026-11-06 |
| 20 | ACWX iShares MSCI ACWI ex U.S. ETF | iShares (BlackRock) | 0.16% | $28.6M | $17.5B | 2026-11-06 |
| 21 | AVDE Avantis International Equity ETF | Avantis | 0.15% | $28.2M | $19.3B | 2026-11-05 |
| 22 | EFAV iShares MSCI EAFE Min Vol Factor ETF | iShares (BlackRock) | 0.40% | $22.3M | $5.5B | 2026-11-06 |
| 23 | FENI Fidelity Enhanced International ETF | Fidelity | 0.19% | $22.2M | $11.7B | 2026-11-05 |
| 24 | BBH VanEck Biotech ETF | VanEck | 4.17% | $21.6M | $523.9M | 2026-11-05 |
| 25 | ESGD iShares ESG Aware MSCI EAFE ETF | iShares (BlackRock) | 0.17% | $20.2M | $11.6B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
ARGX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.9 | +45.5% | +31.0% | 27 |
| AMGN Amgen Inc | $249.0B | 26.9 | +8.2% | +41.6% | 33 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.8% | 51 |
| REGN Regeneron Pharmaceuticals Inc | $93.6B | 20.5 | +18.6% | +19.5% | 57 |
| ARGX argenx SE American Depositary Shares | $58.3B | — | — | +14.6% | 56 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.1% | 100 |
| Peer median | $120.1B | 35.4 | +9.3% | +39.4% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.35M
SI % of Float
2.15%
Days to Cover
2.49
Short Vol Ratio
46.4%
Free Float
—
Float %
—
Short interest 2026-10-15 • Short volume 2026-11-06